SER Serina Therapeutics, Inc.

CIK 0001708599 50 ready 8-Ks latest June 24, 2026, 4:10 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing June 24, 2026, 4:10 PM ET

Top materiality 1.00

Event mix other_material ×19 · earnings ×10 · leadership ×9

Sentiment 13 pos · 9 neg · 28 neu

Latest earnings reported 2026-Q1

Executive change recent →

SHENANIGAN SCORE 3 / 7 see the board

Recent 8-K filings for SER

Highest-materiality recent filing

AgeX completes reverse merger with Serina; becomes Serina Therapeutics, trades as SER

April 1, 2024, 7:59 PM ET M&A materiality 1.00 neutral item 2.01 item 1.01 item 9.01 item 2.03 item 3.03 item 5.01 item 5.02 item 5.03 item 8.01 ◈ executive_change ×5◈ Debt Financings◈ Governance Changes◈ M&A Transactions◈ Material Agreements

Merger closed March 26, 2024; Serina shares converted at 0.97682654 per AgeX share; 5,913,277 shares issued to Serina stockholders.
Post-merger ~10.1M shares outstanding (fully diluted excl. warrants); Serina equityholders own ~75%, AgeX legacy ~25%.

Read filing →

June 24, 2026, 4:10 PM ET other material materiality 0.70 neutral item 5.03 item 5.07 item 9.01

Serina increases authorized common stock from 40M to 125M; equity plan expanded by 2M shares

Authorized common stock increased from 40,000,000 to 125,000,000 shares via filed certificate of amendment.
May 14, 2026, 4:05 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01 ◈ Earnings Releases

Serina Therapeutics Q1 2026 net loss $6.9M; Phase 1b study of SER-252 underway

Net loss of $6.9M ($0.58 per share) for Q1 2026 vs. $4.8M ($0.49) in Q1 2025.
April 21, 2026, 7:59 PM ET leadership materiality 0.35 neutral item 5.02 item 5.03 item 9.01 ◈ Governance Changes

Serina appoints CTO, raises CEO salary to $500K, amends bylaws for Co-Chairs

Srini Tenjarla, Ph.D., promoted to CTO of Serina (AL) subsidiary; salary increased to $425,000 retroactive to Mar 15, 2026.
March 25, 2026, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01 ◈ Earnings Releases

Serina Therapeutics reports FY2025 net loss of $19.4M; SER-252 Phase 1b initiated; up to $30M financing closed

Net loss $19.4M ($1.91/share) vs $11.1M ($1.51/share) in FY2024; operating expenses rose to $24.2M from $17.1M.
March 23, 2026, 7:59 PM ET other material materiality 0.85 positive item 1.01 item 3.02 item 5.02 item 5.03 item 7.01 item 9.01 ◈ Material Agreements ×2◈ Governance Changes

Serina raises $15M first tranche (up to $30M) at $2.25/share (68% premium); Greg Bailey appointed Co-Chairman

First tranche of $15M closed March 20, 2026; second tranche up to $15M due by April 30, 2026.
January 28, 2026, 6:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

Serina Therapeutics receives FDA clearance for SER-252 IND in advanced Parkinson's

FDA cleared IND for SER-252, an investigational therapy for advanced Parkinson's disease.
January 15, 2026, 6:59 PM ET regulatory materiality 0.75 negative item 3.01 item 7.01 item 9.01 ◈ Listing & Compliance Notices

Serina Therapeutics receives NYSE American deficiency notice for stockholders' equity below $2M

Stockholders' equity was $1.6M as of Sept 30, 2025, below $2M, $4M, and $6M thresholds.
December 10, 2025, 6:59 PM ET regulatory materiality 0.70 neutral item 8.01 item 9.01

Serina submits complete response to FDA clinical hold for SER-252 Parkinson's program

Complete response submitted Dec 9, 2025, addressing FDA's clinical hold on SER-252 related to trehalose excipient.
November 13, 2025, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Serina Therapeutics Q3 net loss $4.6M; FDA places SER-252 on clinical hold

Net loss of $4.6M ($0.45 per share) vs net income of $1.4M in Q3 2024.
November 12, 2025, 6:59 PM ET other material materiality 0.15 neutral item 5.07 item 9.01

Serina Therapeutics stockholders elect directors and ratify auditors at 2025 annual meeting

Steve Ledger and Karen J. Wilson elected as directors with over 4.1M votes For each.
November 3, 2025, 6:59 PM ET regulatory materiality 0.85 negative item 8.01 item 9.01

Serina Therapeutics announces FDA clinical hold on SER-252 IND for advanced Parkinson's disease

FDA placed clinical hold on SER-252 IND, requesting additional info on a commonly used excipient; not related to active drug or mechanism.
October 6, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Serina Therapeutics draws first $5M tranche from $20M note for SER-252 Parkinson's trial

Received $5 million initial tranche under up to $20 million convertible note financing agreement.
September 15, 2025, 7:59 PM ET debt materiality 0.65 neutral item 1.01 item 2.03 item 3.02 item 9.01 ◈ Equity Issuances ×2◈ Debt Financings

Serina Therapeutics enters up to $20M convertible note from director Gregory H. Bailey for clinical study SER-252-1b

Up to $20M drawn in 5 tranches tied to milestones for SER-252-1b registrational study; $5M available by Sept 30, 2025.
September 9, 2025, 7:59 PM ET debt materiality 0.65 positive item 7.01 item 9.01

Serina Therapeutics Secures Up to $20M in Convertible Note for Parkinson's Trial

Unsecured convertible note up to $20M in five tranches tied to clinical milestones; first $5M available by Oct 1, 2025.
August 25, 2025, 7:59 PM ET other material materiality 0.70 positive item 8.01 item 9.01

FDA feedback supports registrational trial for SER-252 in advanced Parkinson's under 505(b)(2) NDA pathway

FDA Type B meeting written feedback supports advancing SER-252 (POZ-apomorphine) in registrational study.
August 22, 2025, 7:59 PM ET other material materiality 0.25 neutral item 5.03 item 9.01 ◈ Governance Changes

Serina Therapeutics amends bylaws to add safe harbor procedures and expand forum selection clause

Board adopted Bylaws Amendment on August 18, 2025, effective immediately.
August 11, 2025, 7:59 PM ET earnings materiality 0.60 negative item 2.02 item 9.01

Serina Therapeutics Q2 net loss $6.4M; cash runway into Q4 2025; SER-252 on track for clinic this year

Net loss $6.4M ($0.66/share) vs prior-year net income $5.2M ($0.61/share).
July 29, 2025, 7:59 PM ET other material materiality 0.55 positive item 7.01 item 9.01

Serina advances SER-270 (POZ-VMAT2i) once-weekly injectable into TD development

SER-270 is a long-acting, once-weekly subcutaneous VMAT2 inhibitor for tardive dyskinesia (TD).
July 1, 2025, 7:59 PM ET other materiality 0.10 neutral item 5.08 item 8.01 item 7.01 item 9.01

Serina Therapeutics sets 2025 annual meeting for Nov 7; updates proposal deadlines

Annual meeting scheduled for November 7, 2025; location and time in proxy.
May 22, 2025, 7:59 PM ET leadership materiality 0.65 neutral item 5.02 item 5.03 item 7.01 item 9.01 ◈ executive_change ×2

Serina appoints ex-Karuna CMO Brannan to board; director Gross departs

Appointed Dr. Stephen Brannan (former Karuna CMO) to board and Compensation Committee, effective May 22, 2025.
May 8, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Serina Therapeutics Q1 net loss $4.8M; cash runway through Q3 2025

Net loss attributable to Serina of $4.8M ($0.49/share) vs $15.0M ($5.38/share) in Q1 2024.
April 29, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 8.01 item 9.01

Serina Therapeutics enters ATM facility for up to $13.3M common stock sale

Entered Capital on Demand Sales Agreement with JonesTrading for at-the-market offering of up to $13,270,500 in common stock.
April 15, 2025, 7:59 PM ET other materiality 0.55 positive item 7.01 item 9.01

Serina presents POZ-lipid LNP data showing no immune response in rats, solving PEG antibody issue

POZ-lipid did not trigger IgM or IgG response after repeat dosing in rats in a vaccine format.
April 14, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 3.02 item 3.03 item 5.03 item 7.01 item 9.01 ◈ Governance Changes

Serina Therapeutics raises $5M via convertible preferred stock for Parkinson's drug SER-252

Issued 962,250 shares of Series A Convertible Preferred at $5.18/share for ~$5M gross proceeds.
April 7, 2025, 7:59 PM ET other material materiality 0.10 neutral item 7.01 item 9.01

Serina Therapeutics CEO to present at Jones Healthcare and Technology Innovation Conference on April 9

CEO Steve Ledger will present at the conference in Las Vegas, NV on April 9, 2025 at 3:00 p.m. PDT.
March 24, 2025, 7:59 PM ET other material materiality 0.70 positive item 7.01 item 9.01

Serina presents non-immunogenic POZ-lipid data at ACS 2025 meeting

Randall Moreadith, M.D., Ph.D., Chief Development Officer, presented at ACS Spring 2025 in San Diego.
March 24, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Serina Therapeutics posts FY 2024 net loss of $11.1M vs net income of $5.3M in 2023

Revenues fell to $56K from $3.2M; operating expenses rose to $17.1M from $6.3M.
February 12, 2025, 6:59 PM ET leadership materiality 0.40 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

Serina Therapeutics appoints Dr. Jay Venkatesan to board; Dr. Milton Harris becomes Director Emeritus

Dr. Jay Venkatesan appointed to Board effective Feb 12, 2025; will serve as Audit Committee Chair and on Nominating/Governance Committee.
February 3, 2025, 6:59 PM ET other material materiality 0.70 positive item 7.01 item 9.01

Serina Therapeutics closes $5M second tranche of equity financing at 113% premium

Received second $5M tranche of $10M equity financing from JuvVentures (UK) Limited.
January 15, 2025, 6:59 PM ET leadership materiality 0.45 neutral item 5.02 item 9.01 ◈ executive_change ×2

Serina Therapeutics appoints Karen J. Wilson to board; Steven Mintz departs

Karen J. Wilson appointed effective Jan 14, 2025; over 30 years life sciences finance experience, CPA.
January 6, 2025, 6:59 PM ET other material materiality 0.20 neutral item 2.02 item 7.01 item 9.01

Serina Therapeutics files investor presentation with preliminary 2024 data; no specific figures disclosed

Exhibit 99.1 provides a presentation highlighting Serina's POZ Platform for drug delivery.
December 26, 2024, 6:59 PM ET M&A materiality 0.75 neutral item 1.01 item 2.01 item 9.01 ◈ M&A Transactions

Serina sells UniverXome subsidiary to Juvenescence affiliate for $10 plus assumption of ~$11.2M debt

Sold UniverXome (holding ReCyte and Reverse Bio) to JuvVentures for $10 and assumption of ~$11.2M secured debt.
December 18, 2024, 6:59 PM ET other material materiality 0.35 neutral item 5.02 item 5.07 item 9.01

Serina shareholders approve equity plan amendment increasing share reserve by 950,000 shares

Shareholders approved Amendment to 2024 Equity Incentive Plan, increasing shares reserved by 950,000 to 2,675,000.
December 11, 2024, 6:59 PM ET other material materiality 0.60 positive item 7.01 item 9.01

Serina Therapeutics presents data showing POZ-lipid avoids anti-PEG immune response in animal model

POZ-lipid did not induce IgM or IgG antibody responses after repeated administration in an animal model.
December 2, 2024, 6:59 PM ET other material materiality 0.70 positive item 1.01 item 3.02 item 8.01 item 9.01

Serina Therapeutics secures $10M equity financing from Juvenescence at $10/share (120% premium)

Financing of 1M shares at $10/share, a 120% premium to Nov 26 closing price.
November 12, 2024, 6:59 PM ET earnings materiality 0.90 negative item 2.02 item 9.01

Serina Therapeutics reports Q3 net income of $1.4M but raises going concern doubt as cash stands at $3.2M

Net income $1.4M ($0.16 basic EPS) vs $1.8M a year ago; revenue $14k from NIH grants.
October 2, 2024, 7:59 PM ET other materiality 0.10 neutral item 7.01 item 9.01

Serina Therapeutics presents at Injectables Summit with Enable on SER-252 for Parkinson's

Serina's CDO Randall Moreadith presents at 14th Annual Injectables Summit in Boston on October 2, 2024.
September 12, 2024, 7:59 PM ET leadership materiality 0.65 neutral item 5.02 item 9.01 ◈ executive_change

Serina Therapeutics appoints Steven Ledger as permanent CEO; base $450k, options grant

Steven Ledger, interim CEO since March 2024, appointed permanent CEO effective Sept 8, 2024.
September 5, 2024, 7:59 PM ET other material materiality 0.10 neutral item 7.01 item 9.01

Serina Therapeutics to present at H.C. Wainwright conference on Sept 11

Interim CEO Steve Ledger to present at H.C. Wainwright 26th Annual Global Investment Conference.
August 16, 2024, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change ×2

Serina Therapeutics appoints Gregory S. Curhan as CFO, replaces departing interim CFO Andrea Park

Gregory S. Curhan appointed CFO effective Aug 16, 2024; compensated at $650/hour plus 250k-share option vesting over 48 months.
August 9, 2024, 7:59 PM ET earnings materiality 0.85 negative item 2.02 item 9.01

Serina Therapeutics reports Q2 net income $5.2M but warns of going concern doubt

Net income $5.2M ($0.61 basic EPS) includes $9.3M non-cash warrant revaluation; operating loss $3.8M.
July 29, 2024, 7:59 PM ET other material materiality 0.30 positive item 7.01 item 9.01

Serina Therapeutics to present POZ-lipid data at mRNA Summit; no anti-PEG antibody response

Randall Moreadith, MD, PhD, CDO, will present at 4th Annual mRNA-Based Therapeutics Summit in Boston, July 29-31, 2024.
July 18, 2024, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 item 8.01 item 9.01 ◈ executive_change

Serina Therapeutics appoints Dr. Srini Tenjarla as SVP of CMC and Formulation

Tenjarla joins from Takeda, where he was VP and Head of Drug Product Development.
July 12, 2024, 7:59 PM ET leadership materiality 0.45 neutral item 5.02 ◈ executive_change

Serina Therapeutics COO Tacey Viegas to retire July 15; consulting agreement extends stock options

Tacey Viegas notified retirement as COO effective July 15, 2024.
June 10, 2024, 7:59 PM ET other material materiality 0.40 positive item 8.01

Juvenescence exercises 377,865 warrants at $13.20 for $4.99M; remaining due Nov 2024 & June 2025

Juvenescence exercised 377,865 post-merger warrants at $13.20/share, generating $4,987,818 in proceeds.
May 14, 2024, 7:59 PM ET earnings materiality 0.85 negative item 2.02 item 9.01 ◈ Earnings Releases

Serina Therapeutics Q1 net loss $9.4M; going concern substantial doubt

Net loss of $9.4M ($3.38/share) vs net income of $1.7M in Q1 2023.
May 3, 2024, 7:59 PM ET other materiality 0.50 neutral item 4.01 item 9.01 ◈ Auditor Changes ×2

Serina Therapeutics replaces Withum with Frazier & Deeter as auditor after merger

Audit committee approved Frazier & Deeter as independent auditor for FY2024, replacing Withum.
April 17, 2024, 7:59 PM ET leadership materiality 0.55 neutral item 5.02 item 9.01 ◈ executive_change

Serina Therapeutics appoints Dr. Simba Gill as Executive Chairman

Dr. Simba Gill appointed Executive Chairman effective April 12, 2024.
April 1, 2024, 7:59 PM ET M&A materiality 1.00 neutral item 2.01 item 1.01 item 9.01 item 2.03 item 3.03 item 5.01 item 5.02 item 5.03 item 8.01 ◈ executive_change ×5◈ Debt Financings◈ Governance Changes◈ M&A Transactions◈ Material Agreements

AgeX completes reverse merger with Serina; becomes Serina Therapeutics, trades as SER

Merger closed March 26, 2024; Serina shares converted at 0.97682654 per AgeX share; 5,913,277 shares issued to Serina stockholders.
March 22, 2024, 7:59 PM ET earnings materiality 0.90 negative item 2.02 item 9.01 ◈ Earnings Releases

AgeX Therapeutics reports FY2023 net loss $14.8M; cash only $0.3M; going concern doubt

Net loss $14.8M in FY2023 vs $10.5M in FY2022; EPS ($13.73) vs ($9.70) (basic/diluted).